Search

Your search keyword '"Mahachie, J"' showing total 9 results
Start Over Author "Mahachie, J"
9 results on '"Mahachie, J"'

2. Safety and cost of infliximab for the treatment of belgian paediatric patients with crohn disease

Author

UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, UCL - (MGD) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Service d'anatomie pathologique, De Greef, E, Hoffman, I., D'Haens, G., van Biervliet, S, Smets, Françoise, Scaillon, M, Dewit, Olivier, Peeters, H, Paquot, I, Alliet, P, Arts, W, Hauser, B, Vermeire, S, van Gossum, A, Rahier, Jean-François, Etienne, Isabelle, Louis, E, Coche, CJ, Mahachie, J, van Steen, K, Veereman, G, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, UCL - (MGD) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Service d'anatomie pathologique, De Greef, E, Hoffman, I., D'Haens, G., van Biervliet, S, Smets, Françoise, Scaillon, M, Dewit, Olivier, Peeters, H, Paquot, I, Alliet, P, Arts, W, Hauser, B, Vermeire, S, van Gossum, A, Rahier, Jean-François, Etienne, Isabelle, Louis, E, Coche, CJ, Mahachie, J, van Steen, K, and Veereman, G

Abstract

Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD.

Published
2012

4. OP12 Multiple functional variants at the 3p21 locus contribute to ulcerative colitis: Results from a European consortium

Author

Cleynen, I., primary, Artieda, M., additional, Verspaget, H., additional, Szczypiorska, M., additional, Seibold, F., additional, Lakatos, P., additional, Ahmad, T., additional, Weersma, R., additional, Mahachie, J., additional, Arijs, I., additional, Müller, S., additional, Parnell, K., additional, Tordai, A., additional, Hommes, D.W., additional, Van Steen, K., additional, Wijmenga, C., additional, Rutgeerts, P., additional, Lottaz, D., additional, and Vermeire, S., additional

Published
2012
Full Text
View/download PDF

5. P320 Factors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn's disease patients (BELCRO)

Author

De Greef, E., primary, Mahachie, J., additional, Hofman, I., additional, Smets, F., additional, Van Biervliet, S., additional, Scaillon, M., additional, Hauser, B., additional, Alliet, P., additional, Arts, W., additional, Dewit, O., additional, Peeters, H., additional, Baert, F., additional, D'Haens, G., additional, Rahier, J.-F., additional, Etienne, I., additional, Bauraind, O., additional, Van Gossum, A., additional, Vermeire, S., additional, Fontaine, F., additional, Muls, V., additional, Louis, E., additional, Van de Mierop, F., additional, Coche, J.-C., additional, Van Steen, K., additional, and Veereman, G., additional

Published
2012
Full Text
View/download PDF

6. OP19 Genetic and functional evidence for a role for CYLD in Crohn's disease: Results from a European consortium

Author

Cleynen, I., primary, Vazeille, E., additional, Artieda, M., additional, Szczypiorska, M., additional, Bringer, M.-A., additional, Verspaget, H., additional, Lakatos, P., additional, Seibold, F., additional, Parnell, K., additional, Weersma, R., additional, Mahachie, J., additional, Morgan-Walsh, R., additional, Staelens, D., additional, Arijs, I., additional, Müller, S., additional, Tordai, A., additional, Hommes, D.W., additional, Ahmad, T., additional, Wijmenga, C., additional, Pender, S., additional, Rutgeerts, P., additional, Lottaz, D., additional, Van Steen, K., additional, Vermeire, S., additional, and Darfeuille-Michaud, A., additional

Published
2012
Full Text
View/download PDF

7. P246 Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease

Author

De Greef, E., primary, Hoffman, I., additional, D'Haens, G., additional, Van Biervliet, S., additional, Smets, F., additional, Scaillon, M., additional, Dewit, O., additional, Peeters, H., additional, Paquot, I., additional, Alliet, P., additional, Arts, W., additional, Hauser, B., additional, Vermeire, S., additional, Van Gossum, A., additional, Rahier, J.-F., additional, Etienne, I., additional, Louis, E., additional, Coche, J.-C., additional, Mahachie, J., additional, Van Steen, K., additional, and Veereman, G., additional

Published
2012
Full Text
View/download PDF

8. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.

Author

Stocker G, Hacker UT, Fiteni F, John Mahachie J, Roth AD, Van Cutsem E, Peeters M, Lordick F, and Mauer M

Subjects
Adenocarcinoma complications, Adenocarcinoma mortality, Adenocarcinoma pathology, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols standards, Body Mass Index, Body Surface Area, Chemotherapy, Adjuvant adverse effects, Chemotherapy, Adjuvant methods, Chemotherapy, Adjuvant standards, Colectomy, Colon pathology, Colon surgery, Colonic Neoplasms complications, Colonic Neoplasms mortality, Colonic Neoplasms pathology, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Dosage Calculations, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local prevention & control, Neoplasm Staging, Practice Guidelines as Topic, Prognosis, Retrospective Studies, Sex Factors, Young Adult, Adenocarcinoma therapy, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Colonic Neoplasms therapy, Neoplasm Recurrence, Local epidemiology, Obesity complications
Abstract

Background: Dose reduction in obese cancer patients has been replaced by fully weight-based dosing recommendations. No data, however, are available on the effects of dose reduction in obese stage III colon cancer patients undergoing adjuvant chemotherapy., Methods: Survival outcomes and toxicity data of obese (body mass index [BMI] ≥30 kg/m 2 ), stage III colon cancer patients treated within the phase III PETACC 3 trial comparing leucovorin, 5-FU (LV5FU2) with LV5FU2 plus irinotecan were analysed retrospectively according to chemotherapy dosing at first infusion (i.e. fully weight-based dosed - versus dose-reduced group). Multivariate analyses on relapse free survival (RFS) and overall survival (OS) were conducted to adjust for baseline prognostic factors using Cox regression model., Results: 13.4% (280 of 2094 patients) had a BMI ≥ 30 kg/m 2 , and 5.3% had both a BMI ≥ 30 kg/m 2 and a body surface area (BSA) ≥2 m 2 . Dose reductions occurred in 16.1% of patients with a BMI ≥ 30 kg/m 2 and 32.4% with BMI ≥ 30 kg/m 2 and BSA ≥ 2 m 2 , respectively. In patients with BMI ≥ 30 kg/m 2 , multivariate analysis demonstrated a trend towards better RFS in the fully dosed compared to the dose-reduced group (Hazard ratio (HR): 0.69, 95% CI: 0.43-1.09; p = 0.11); however, there was no statistically significant difference in OS. In patients with BMI ≥ 30 kg/m 2 and BSA ≥ 2 m 2 , multivariate analysis demonstrated better RFS in fully dosed compared with dose-reduced patients (HR: 0.48, 95% CI: 0.27-0.85; p = 0.01) and a strong trend towards better OS (HR: 0.53, 95% CI: 0.28-1.01; p = 0.052). This group comprised predominantly of men., Conclusions: Data support the recommendation of using fully dosed chemotherapy for the adjuvant treatment in obese patients with colon cancer., (Copyright © 2018 Elsevier Ltd. All rights reserved.)

Published
2018
Full Text
View/download PDF

9. Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.

Author

Cristina V, Mahachie J, Mauer M, Buclin T, Van Cutsem E, Roth A, and Wagner AD

Subjects
Aged, Female, Gastrointestinal Neoplasms pathology, Humans, Male, Middle Aged, Retrospective Studies, Drug Therapy methods, Drug-Related Side Effects and Adverse Reactions epidemiology, Gastrointestinal Neoplasms complications, Gastrointestinal Neoplasms drug therapy, Gender Identity
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results